Entera Bio Ltd.

5.11-0.0800-1.54%Vol 92.83K1Y Perf 184.44%
Jul 27th, 2021 14:52 DELAYED
BID5.11 ASK5.13
Open5.20 Previous Close5.19
Pre-Market- After-Market-
 - -%  - -
Target Price
12.00 
Analyst Rating
Strong Buy 1.00
Potential %
134.38 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap121.11M 
Earnings Rating
Neutral
Price Range Ratio 52W %
44.87 
Earnings Date
19th Aug 2021

Today's Price Range

4.965.20

52W Range

1.0010.16

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-1.70%
1 Month
-13.07%
3 Months
36.58%
6 Months
260.42%
1 Year
184.44%
3 Years
-6.32%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ENTX5.11-0.0800-1.54
AAPL146.70-2.2900-1.54
GOOG2 732.14-60.7500-2.18
MSFT285.84-3.2100-1.11
XOM57.63-0.8500-1.45
WFC45.040.03000.07
JNJ172.280.41000.24
FB366.59-5.8700-1.58
GE13.110.19001.47
JPM151.51-0.1400-0.09
Earnings HistoryEstimateReportedSurprise %
Q01 2021--0.43-
Q03 2020--0.09-
Q02 2020--0.17-
Q01 2020--0.16-
Q04 2019--0.26-
Q03 2019--0.25-
Q02 2019--0.12-
Q01 2019--0.26-
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.1078.72Positive
9/2021 QR-0.1080.39Positive
12/2021 FY-0.78--
12/2022 FY-0.57--
Next Report Date19th Aug 2021
Estimated EPS Next Report-0.10
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume92.83K
Shares Outstanding23.70M
Trades Count613
Dollar Volume546.17K
Avg. Volume5.27M
Avg. Weekly Volume206.66K
Avg. Monthly Volume584.93K
Avg. Quarterly Volume3.21M

Entera Bio Ltd. (NASDAQ: ENTX) stock closed at 5.19 per share at the end of the most recent trading day (a -2.26% change compared to the prior day closing price) with a volume of 85.64K shares and market capitalization of 121.11M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 24 people. Entera Bio Ltd. CEO is Adam Gridley.

The one-year performance of Entera Bio Ltd. stock is 184.44%, while year-to-date (YTD) performance is 380.56%. ENTX stock has a five-year performance of %. Its 52-week range is between 1 and 10.16, which gives ENTX stock a 52-week price range ratio of 44.87%

Entera Bio Ltd. currently has a PE ratio of -, a price-to-book (PB) ratio of 8.55, a price-to-sale (PS) ratio of 221.11, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -102.49%, a ROC of -175.41% and a ROE of -155.38%. The company’s profit margin is -%, its EBITDA margin is -2 152.30%, and its revenue ttm is $428.00 Thousand , which makes it $0.02 revenue per share.

Of the last four earnings reports from Entera Bio Ltd., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.10 for the next earnings report. Entera Bio Ltd.’s next earnings report date is 19th Aug 2021.

The consensus rating of Wall Street analysts for Entera Bio Ltd. is Strong Buy (1), with a target price of $12, which is +134.38% compared to the current price. The earnings rating for Entera Bio Ltd. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Entera Bio Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Entera Bio Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 31.88, ATR14 : 0.42, CCI20 : -83.84, Chaikin Money Flow : 0.22, MACD : 0.15, Money Flow Index : 39.64, ROC : -11.13, RSI : 48.94, STOCH (14,3) : 26.67, STOCH RSI : 0.00, UO : 58.47, Williams %R : -73.33), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Entera Bio Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company which focuses on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The lead oral parathyroid hormone (PTH) product candidate, EB612 for the treatment of hypoparathyroidism. The company also develops a varied oral PTH product candidate, EB613 for the treatment of osteoporosis.

CEO: Adam Gridley

Telephone:

Address: 37 Walnut Street, Wellesley Hills 02481, MA, US

Number of employees: 24

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

70%30%

Bearish Bullish

56%44%

Bearish Bullish

51%49%

News

Stocktwits